newsfilter
← Latest News
GlobeNewswire·

BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis

This 2nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy data The Company is to report the recommendation from the DMC based on its review of second interim analysis by end of Q2 2021,